Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study

• DOI: 10.1136/rmdopen-2020-001519
• Publication Date: 2021-02-17T00:12:31Z
• Authors: Roberta Ramonda; Mariagrazia Lorenzin; Antonio Carriero; Maria Sole Chimenti; Raffaele Scarpa; Antonio Marchesoni; Ennio Lubrano; Carlo Salvarani; Alberto Cauli; Angelo Semeraro; Leonardo Santo; Augusta Ortolan; Andrea Doria; Elena Fracassi; Giulia Virelli; Marco Masia; Rosalinda Fanizzi; Elisa Visalli; Giorgio Amato; Antonio Carletto; Rosario Foti
• Keywords: Erythrocyte sedimentation rate; Discontinuation

Objectives To evaluate in a multicentric Italian cohort of patients with psoriatic arthritis (PsA) on secukinumab followed for 24 months: (1) the long-term effectiveness and safety secukinumab, (2) drug retention rate minimal disease activity (MDA), (3) differences outcomes according to biological treatment line: biologic-naïve ( group A ) versus multifailure B patients. Methods Consecutive PsA receiving were evaluated prospectively. Disease characteristics, previous/ongoing treatments, comorbidities follow-up duration collected. activity/functional/clinimetric scores biochemical values recorded at baseline (T0), 6(T6), 12(T12) 24(T24) months. Effectiveness was overtime descriptive statistics; multivariate Cox logistic regression models used predictors drug-discontinuation MDA T6. Infections adverse events recorded. Results 608 (41.28% men; mean (SD) age 52.78 (11.33)) enrolled; prescribed as first-line 227 (37.34%) patients, second (or more)-line 381 (62.66%). shown an improvement several outcomes, such Ankylosing Spondylitis Activity Score (T0=3.26 (0.88) vs T24=1.60 (0.69) ;p=0.02) Index Psoriatic Arthritis (T0=25.29 (11.14) T24=7.69 (4.51); p<0.01). At T24, showed lower Psoriasis Area Severity (p=0.04), erythrocyte sedimentation C reactive protein (p=0.03 ;p=0.05) joint count (p=0.03) compared . achieved 75.71% 70.37% Treatment discontinued 123 (20.23%) mainly due primary/secondary loss effectiveness, 22 events. Retention T24 71% whole population, some difference depending dosage (p=0.004) gender (p=0.05). Conclusions In real-life clinical setting, secukimumab proved safe effective all domains, notable rate.